Laura Berezin

Cooley advised Kyverna Therapeutics on its $85 million Series B financing. Partners Laura Berezin and Sara Semnani led the Cooley team advising Kyverna, a developer of new cell-based therapeutics designed to offer treatments and cures for serious autoimmune and inflammatory diseases.

Cooley advised Five Prime Therapeutics, a publicly traded clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, on its agreement to sell to Amgen in an all-cash transaction with an equity value of approximately $1.9 billion. Partners Jamie Leigh, Ian Nussbaum and Laura Berezin led the Cooley team advising Five Prime.

Cooley advised Ovid on its $75 million initial public offering of 5,000,000 shares of common stock. Ovid, which now trades on The NASDAQ Global Select Market as “OVID,” is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.

Cooley advised underwriters on ALX Oncology’s $185.7 million initial public offering of 9,775,000 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Jefferies, Credit Suisse, Piper Sandler and Cantor acted as joint book-running managers and LifeSci Capital acted as lead manager for the offering. ALX Oncology’s securities now trade on the Nasdaq Global Select Market under the symbol “ALXO.” Partners Dave Peinsipp, Kristin VanderPas, and Laura Berezin led the Cooley team.

Cooley advised Vir Biotechnology on its $142.9 million initial public offering of 7,142,858 shares of common stock. Vir Biotechnology, whose securities now trade on Nasdaq Global Select Market under the symbol "VIR", is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Partners Laura Berezin, Charlie Kim and Kristin VanderPas led the Cooley team.